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Abstract
Background: Laser ablation with a neodymium-doped yttrium aluminum garnet (Nd:YAG) laser is a minimally
invasive approach which is able to achieve a precise tissue necrosis. The study was aimed to assess the feasibility and
efficiency of laser ablation in the treatment of retroperitoneal and hepatic portal unresectable metastatic lymph nodes.
Methods: Eight patients including 11 pathologically proven metastatic lymph nodes, 4 in retroperitoneal, 7 in hepatic
portal region, were treated by laser ablation. Primary cancers were cholangiocarcinoma (n = 4) and hepatocellular
carcinoma (n = 4). Under sonographic guidance, the laser ablation was performed percutaneously. Follow-up contrast
computed tomography or magnetic resonance image was performed.
Results: The treatments were completed in single process in all the patients. No severe complications occurred.
Follow-up contrast computed tomography or magnetic resonance imaging at 1 and 3 months showed partial
responses in 11 lymph nodes. The local response rate at the 6 month follow-up was 75.0 %. The overall response
rate was 62.5 %. Abdominal pain scores decreased significantly in all patients. Tumor marker levels decreased in
six patients. The Child-Pugh grade did not change.
Conclusions: The results suggest that sonographically guided laser ablation is technically feasible for the local
treatment of unresectable retroperitoneal and hepatic portal lymph nodes from hepatic cancer. Although further
study is needed to evaluate its long time efficacy, abdominal pain relief is prominent.
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Background
The common therapies for unresectable metastases
are radiotherapy or chemotherapy [1–5]. However,
radiotherapy is contraindicated when the radiation
dose reaches the upper limit. Some of patients cannot
endure the treatment course due to side effects
caused by chemotherapy. Image-guided local therapy
is a minimally invasive method that can be performed
percutaneously. It includes two main technologies:
thermotherapy and chemical ablation. Thermotherapy
includes radiofrequency ablation, microwave ablation,
laser ablation, and high-intensity-focused ultrasound
ablation. Chemical ablation includes local injection of
ethanol or acetic acid [6–8]. In this technique, the
therapeutic electrode or injection needle is inserted
into the target region under computed tomography,
magnetic resonance, or ultrasound guidance. Radiofre-
quency ablation and laser ablation has been consid-
ered equally effective in treating small hepatocellular
carcinoma [6]. Moreover, radiofrequency ablation is
considered the first-line treatment in some hepatocel-
lular carcinoma and seems to be comparable to surgi-
cal resection in terms of survival outcomes [7, 8].
The advantages of this kind of therapy are local
coagulation of malignancies with good toleration in
fragile patients and few systemic adverse reactions.
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Therefore, in the last decade, it has become an ef-
fective therapy for some recurrent or unresectable
malignancies.
However, the metastases in the hepatic portal or retro-
peritoneal space are considered to be “critical lesions”
and are difficult to be treated by radiofrequency and
microwave ablation [9, 10]. The main reason is that
blood flow carries away part of the general heat resulting
in the “heat-sink” effect [10]. Residual tumor was ob-
served in 100 % of tumors adjacent to the inferior vena
cava, in 57 % of tumors adjacent to the portal vein, and
in 33 % of tumors adjacent to the hepatic veins [11]. At
the same time, with a large diameter of the needle, usu-
ally 16 Ga, unintentional injury of the great vessels can
produce potentially fatal hemorrhage [9]. Ethanol injec-
tion therapy using a 21-Ga needle may decrease the risk
in injury of great vessels. However, the liquid can be dis-
tributed non-uniformly due to intratumoral septa, which
results in incomplete necrosis [8, 12]. Furthermore, a
larger number of treatment sessions are required for
each lesion, and recurrence or needle track seeding, par-
ticularly in tumors greater than 2 cm, is possible [12].
The use of neodymium-doped yttrium aluminum
garnet (Nd:YAG) laser ablation provides more accur-
ate thermal field control. It has been used in many
conditions such as endobronchial therapy [13], pros-
tate diseases [14, 15], and thyroid tumors [16–18].
Usually, a fiber of only 300 μm in diameter is re-
quired. In some studies, laser ablation has also been
used in hepatocellular carcinoma [19–21] and consid-
ered to be a component of the multimodality treat-
ment of liver metastases from colorectal cancer and
neuroendocrine carcinomas [22, 23]. The tumor loca-
tion does not have a significant negative effect on the
effectiveness, safety, or ability to achieve local control
of disease. The aim of this study was to apply laser
ablation to retroperitoneal and hepatic portal meta-
static lymph nodes to assess the safety, feasibility, and
efficiency of this treatment in these high-risk areas.
Methods
Patients
The study was approved by the Institutional Review
Board at the First Affiliated Hospital, College of
Medicine, Zhejiang University. The procedures were
conducted according to the principles of the Helsinki
Declaration. Written informed consent was obtained
from the patients for publication and the accompany-
ing images.
From August 2012 to January 2014, eight patients (six
men, two women, age range 36–58 years old, mean age
48.0 years old, follow-up period 6 months) underwent
sonograghically guided laser ablation. All patients were
examined by an interdisciplinary tumor board including
surgeon, radiologist, hepatologist, and oncologist. All the
patients had a history of surgery for liver cancer and at
least one cycle of chemotherapy or radiotherapy. No pa-
tients were good candidates for surgical resection of the
lymph nodes. Inclusion criteria were (1) metastatic
lymph nodes in the retroperitoneum or hepatic portal of
liver cancer, (2) a single lymph node less than 5 cm or
multiple lymph nodes (no more than three) less than
3 cm, (3) inadequate response to chemotherapy or radio-
therapy: continued enlargement of lesion by more than
20 % in spite of sorafenib treatment for 2 months or
treatment with maximum dosage of radiotherapy or dis-
continuation of these treatments because of serious ad-
verse reactions, and (4) target lymph nodes could be
revealed by ultrasound. Exclusion criteria were patients
with clotting impairment, renal failure, or Child-Pugh
grade C cirrhosis. The primary cancers and numbers of
cases were cholangiocarcinoma (CCA) 4 and hepatocel-
lular carcinoma (HCC) 4. The target metastatic lymph
nodes in the study consisted of four in the retroperito-
neum (two in a patient with CCA, two in a patient with
HCC)and seven in the hepatic portal region (two in two
patients with CCA and five in four patients with HCC).
Lymph node size (maximum diameter) ranged from 15
to 31 mm (mean 21.3 mm).
Patients were symptomatic including abdominal
pain, weakness, and weight lost. The pain score was
assessed before and after treatment according to the
criteria described previously [24]: grade 0, no pain;
grade 1, mild pain that does not interfere with func-
tion; grade 2, moderate pain or pain or analgesics
that interferes with function but does not interfere
with activities of daily living; grade 3, severe pain or
pain or analgesics that severely interferes with activ-
ities of daily living; and grade 4, disabling pain.
All lymph nodes were histologically proven to be
metastases of primary cancer by sonographically guided
biopsy before laser ablation.
Treatment procedure
Immediately prior to laser ablation, contrast-enhanced
ultrasound (CEUS) was used to determine the borders,
locations, and sizes of the lymph nodes. The contrast
agent, 2.4 mL SonoVue (Bracco, Milan, Italy), was
injected intravenously by bolus injection followed by a
10 mL saline flush. The instrument used was a MyLab
90 (Esaote, Genova, Italy) (Fig. 1) with CA541 trans-
ducer. The transducer is a convex matrix array probe
with a 4–10-MHz frequency. Masses which were en-
hanced by the contrast agent were considered to be tar-
get lymph nodes. The lymph nodes began to be
enhanced immediately after aortic enhancement. The
duration lasted for about 10–30 s. Each target lymph
node size was measured in this arterial phase. The
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distance between lymph node and inferior vena cava,
aorta, and portal vein was measured. The tissue which
was in front of the lymph node was carefully observed
as well because important structures such as pancreas,
bowel, and mesenteric artery should be avoided at the
time of puncture.
Laser ablation was performed by a Nd:YAG laser-
beam fiber ablation system (Echolaser X4, Elesta s.r.l.
Florence, Italy) in a continuous mode, with a wavelength
of 1064 nm in which the penetration of light in the in-
frared spectrum is optimal.
Ultrasound-guided needle insertion into lymph nodes
was performed under general anesthesia. The insertion
route was carefully determined by ultrasound and color
Doppler image to avoid the pancreas, bowel, vessels, or
bile ducts. Care was taken to ensure that the tip of a 21-
Ga needle was 10 mm away from the distal borderline of
the lymph node. After the correct positioning of the tip
of the needle, a 300-μm diameter plane-cut quartz op-
tical bare fiber was advanced through the sheath of the
needle, and the sheath was withdrawn 10 mm to expose
the 10-mm fiber. The output power of laser was set at
3 W, and the duration set for 10 min. Worn fibers auto-
matically block prevent firing of the laser when the sys-
tem is switched on. If the whole lesion did not become
hyperechoic at the end of the first 10 min, in the prox-
imal area of the lymph nodes, the ablation was consid-
ered to be insufficient. In those cases, both the fiber and
the sheath were withdrawn about 2–5 mm. Additional
energy was applied until the lesion became hyperechoic.
The total delivered energy was calculated by the
equipment.
The number of the laser fibers used was depended by
the size of the lymph node. The patient was observed
for 30 min after the treatment for changes in vital signs.
Analysis of therapeutic efficiency
Immediate post-laser ablation, CEUS was performed
by the laser device operator. Images were transferred
to an ultrasound workstation and evaluated by an-
other doctor with 5 years of experience with CEUS
and who was blinded to the protocol. The target area
without enhancement by SonoVue was defined as
success. The mechanism is based on obstruction of
the tumor blood supply by the coagulation necrosis
of the target lesion after laser therapy. If there was area in
the target lesion that was enhanced by SonoVue, it was
defined as a residual area. Then, an additional laser abla-
tion was done immediately and CEUS was performed after
that treatment. One month after laser ablation, MRI
or contrast-enhanced CT scans were performed to
evaluate the efficiency of therapy and then every
3 months. Child-Pugh grade and tumor markers in-
cluding serum alpha fetoprotein (AFP) levels for HCC
and carbohydrate antigen 19-9 (CA19-9) levels for
CCA were measured.
Follow-up MRI or CT scans were evaluated by an
experienced radiologist who was blinded to the therapy.
Therapeutic efficiency was assessed by the criteria for
image-guided tumor ablation [25]: (1) complete
Fig. 1 The equipment of MyLab 90 (Esaote, Genova, Italy) together with laser ablation instrument and the picture of laser fiber
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response (CR) was defined as complete disappearance
of the target tumor enhancement detectable by imaging
analysis, (2) partial response (PR) was defined as the re-
duction of the target tumor enhancement by >50 %
compared to the pre-procedure value, (3) no change
(NC) was defined as a decrease of <50 % or an in-
crease of <25 % in contrast enhancement in the tar-
get area compared to the pre-procedure value, and
(4) lymph node progression (LP) was defined as an
increase of >25 % contrast enhancement or enlargement
of the lymph node in the target area. Local response rate
(LRR) was calculated as (CR number + PR number)/total
number of cases × 100 % [25]. The appearance of new
lymph nodes or metastasis elsewhere was also assessed in
follow-up. The overall response rate (ORR) was calculated
as (CR number + PR number − progression elsewhere)/
total number of cases × 100 %.
Statistical analysis: All values were expressed as mean
± SD and statistically analyzed by pared t test with SPSS
19.0 software. A p value less than 0.05 was defined as
statistically significant.
Results
Ultrasound guidance and the laser ablation
During laser energy application, ultrasound images
showed a hyperechoic area around the fiber tip.
When the procedure was completed, the whole lesion
consisted of a hyperechoic zone (Fig. 2). Laser energy
and the number of laser fibers are listed in Table 1.
All the lymph nodes were treated by single therapies
because no residual enhancement area was found by
immediate CEUS.
Clinical follow-up
One-month follow-up MRI or CT scans showed that all
lymph nodes had partial responses with decreased en-
hancement by about 81–90 % (Fig. 3).
At the 3-month follow-up point, one patient was
found to have left kidney metastasis and a liver can-
cer progression. He died from cerebral hemorrhage
4 months after laser ablation. Seven patients survived
by the 6 month follow-up. Six patients had local partial re-
sponses. One patient had lymph node progression with
Fig. 2 Ultrasound images in case 1 with a retroperitoneal metastatic lymph node. a Two optical fibers (hollow arrow) were inserted into the
hypoechoic nodule (arrow). b After laser ablation, the nodule was reviewed as a hyperechoic lesion. c The nodule was enhanced by SonoVue
injection in contrast-enhanced ultrasound before laser ablation. d There was no enhancement in the nodule by SonoVue injection immediately
after laser ablation
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two new lymph nodes. One patient had progression in the
liver (Table 1). The LRR at the 6 month follow-up was
75.0 %, and the ORR was 62.5 %.
The pain score decreased significantly after treatment
in the follow-up period (Table 2).
There were no changes in Child-Pugh grades after
laser ablation in any patients (Table 3). Serum AFP
decreased significantly in 1-month follow-up but not
significantly in 3 and 6-month follow-ups. CA19-9 de-
creased significantly in 3 and 6 month follow-ups but
not in 1 month follow-up (Table 3).
Adverse reaction
There were no major complications detected in the pa-
tients during the laser ablation. Low grade to moderate
grade fever lasting for 2–4 days after the procedure was
detected in seven patients. These resolved with symp-
tomatic treatment.
Discussion
Laser ablation is one of the thermal therapies that can
be used for local control of malignant tumors [19, 20,
24–26]. In the current study, we treated retroperitoneal/
hepatic portal lymph nodes by a Nd:YAG laser-beam
fiber ablation and found good local response of the ma-
lignancies at the 6-month follow-up. To the best of our
knowledge, this is the first report in the treatment of
metastatic lymph nodes in abdomen by laser ablation.
Retroperitoneal lymph node metastasis is one of the
signs of advanced or terminal stage of malignancy.
Treatment by ethanol injection and radio frequency ab-
lation has been reported [27–29]. We believe that the
main advantage of applying Nd:YAG laser ablation is the
use of fine needles, which are less traumatic and can be
handled more easily by the operator to reach difficult
sites. On the other hand, Nd:YAG lasers with a wave-
length of 1064 nm were used because the penetration of
Table 1 Characteristics of patients and their follow-up imaging results
Gender Primary
cancer
Size (mm) Location Number
of fibers







Case 1 m CCA 31 × 25 Retroperitoneum 2 3 3600 PR PR NA Liver and left kidney
progression in
3-month follow-up
Case 2 m HCC 24 × 12 Hepatic portal 1 3 3000 PR PR PR No
18 × 15 Hepatic portal 1 3 2700 PR PR PR
Case 3 f HCC 20 × 14 Hepatic portal 1 3 2700 PR PR PR No
Case 4 m CCA 31 × 21 Hepatic portal 2 3 3600 PR PR PR Liver progression in
6-month follow-up
Case 5 m HCC 15 × 12 Hepatic portal 1 3 1800 PR PR PR No
15 × 11 Hepatic portal 1 3 1800 PR PR PR
Case 6 m CCA 15 × 12 Hepatic portal 1 3 1800 PR PR PR No
Case 7 f HCC 18 × 14 Retroperitoneum 1 3 2700 PR PR PR New lymph nodes in
retroperitoneum in
6-month follow-up28 × 19 Retroperitoneum 2 3 3600 PR PR LP
Case 8 m CCA 18 × 14 Retroperitoneum 1 3 1800 PR PR PR No
CCA cholangiocarcinoma, HCC hepatocellular carcinoma, CR complete response, PR partial response, LP lymph node progression, NA not available
Fig. 3 Contrast-enhanced CT pre-treatment and 1 month MRI follow-up images from Case 1, a patient with retroperitoneal metastatic lymph
node (arrow) treated with laser ablation. a: Contrast-enhanced CT showed that a lymph node was enhanced heterogeneously in arterial phase.
b: There was reduction enhancement of the nodule about 88 % by gadoxetic acid-enhanced MRI in arterial phase indicating a local partial response
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light is optimal in the near infrared spectrum. This
type of laser has been commonly used in interstitial
ablation [6].
CT-guided interventional therapies are widely used.
However, the CT scan is limited to cross-sectional anat-
omy [30]. Ultrasound scanning including color Doppler
imaging is feasible to avoid damage to the vessels and
organs because it can target the needle in virtually any
plane. Therefore, it is possible to choose a safe route,
and real-time ultrasound imaging can track the advance-
ment of the needle. In the current study, we used ultra-
sound to guide the insertion of Nd:YAG laser fibers. No
significant puncture-related complications occurred.
Moreover, CEUS evaluates ablation effect immediately
and decisions on whether additional therapy is required
can be made immediately.
In most studies, it has been reported that the treat-
ment of lesions close to the great vessels was more
likely to result in residual tumor because of the heat-
sink effect of blood flow [7, 9, 10, 29]. In the current
study, the lymph nodes either close to the aorta, in-
ferior vena cava, or portal vein had a local response
rate of 75.0 % and overall response rate of 62.5 %.
Tumor markers decreased significantly in some pa-
tients except in two cases with progression else-
where. These data showed that laser ablation benefits
treatment of lesions close to the great vessels. The
laser destruction of tissue including tissue protein
denaturation, coagulative necrosis, tissue liquefaction,
vaporization, and carbonization occurs instantan-
eously. Although part of the heat is removed by
blood flow, the size of the affected area is still
around 12–15 mm in diameter when 3 W of power
were used for 10 min.
In the treatment of lesions close to vessels, the
impact of laser ablation on vessel should also be
considered. If the laser fiber is too close to the ves-
sel, heat will produce tissue damage in the form of
denaturation of proteins within the vessel wall,
stimulation of inflammation, and vein shrinkage and
thrombosis [31]. If the tip of the laser catheter is in
contact with the vessel wall, high-energy absorption
can lead to tissue vaporization, resulting in vessel
perforation. Temperatures above 100 °C will cause
tissue vaporization but produce gas bubbles which do
not increase the risk of embolization [31]. Leakage
into a vessel can cause endothelial damage followed
with thrombosis. We did not observe these vessel
complications in current study perhaps because the
laser fiber was maintained at least 0.5-cm distant
from the adjacent vessel.










1 4 2 2 NA
2 3 1 1 1
3 3 1 1 1
4 4 1 1 1
5 3 1 1 1
6 3 1 1 1
7 4 1 1 2
8 3 1 1 1
Mean ± SD 3.38 ± 0.52 1.12 ± 0.35* 1.12 ± 0.35* 1.14 ± 0.38*
p value 0.000 0.000 0.000
NA not available
*p < 0.05 vs before treatment
Table 3 Child-Pugh grade and serum tumor marker follow-up data

























1 B B B NA 205.1 195.3 105.4 NA
2 B B B B 151.7 65.2 66.8 79.5
3 B B B B 97.6 17.6 35.3 75.1
4 B B B B 545.2 236.1 118.7 302.5
5 A A A A 137.3 54.2 28.6 14.4
6 B B B B 311.2 142.2 147.4 159.9
7 B B B B 84.2 55.9 78.8 153.6
8 B B B B 346.6 102.4 98.4 105.8
















p value 0.015 0.060 0.433 0.066 0.045 0.020
AFP alpha fetoprotein protein, CA19-9 carbohydrate antigen 19-9
*p < 0.05 vs before treatment
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A clinical sign of retroperitoneal lymph node or hep-
atic portal metastasis is abdominal pain due to compres-
sion or infiltration of celiac plexus [32]. Relief or partial
relief of the pain is one of the important treatment aims.
Although analgesia with anesthetics can alleviate the
pain, it has no effect on tumor control. From the current
data, the pain score decreased significantly. Possible ex-
planations include local control of the lymph nodes
which resulted in direct pain palliation and the thermal
effects caused by laser ablation blocked nerves near the
lymph nodes.
There are some limitations to the current study. The
number of patients was very small, and the follow-up
periods were short. Furthermore, only partial responses
were achieved in the study. We think a large study is re-
quired and perhaps a randomized control trial or a pro-
spective cohort study will be necessary to confirm these
results. Various parameters should be studied to estab-
lish the relationship between laser parameters, fiber
number, fiber distance to vessels, distance between adja-
cent fibers, lymph node sizes, and treatment results in
the future.
Conclusions
Laser ablation of the metastatic retroperitoneal lymph
nodes and hepatic portal lymph nodes benefits the treat-
ment of unresectable malignancies.
Abbreviations
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